These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 30226106)

  • 1. A pilot study examining the profile of older people on clozapine.
    Benbow J; Wand AP; Simpson B
    Australas Psychiatry; 2018 Dec; 26(6):619-623. PubMed ID: 30226106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clozapine use in geriatric patients- Challenges.
    Mukku SSR; Sivakumar PT; Varghese M
    Asian J Psychiatr; 2018 Mar; 33():63-67. PubMed ID: 29529421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does cognitive impairment in treatment-resistant and ultra-treatment-resistant schizophrenia differ from that in treatment responders?
    Anderson VM; McIlwain ME; Kydd RR; Russell BR
    Psychiatry Res; 2015 Dec; 230(3):811-8. PubMed ID: 26564550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world.
    Mortimer AM; Singh P; Shepherd CJ; Puthiryackal J
    Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):49-55. PubMed ID: 20643629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathway to clozapine use: a comparison between a patient cohort from New Zealand and a cohort from the United Kingdom.
    Wheeler AJ; Feetam CL; Harrison J
    Clin Drug Investig; 2014 Mar; 34(3):203-11. PubMed ID: 24402882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
    Wheeler AJ
    Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive differences in schizophrenia on long-term treatments with clozapine, risperidone and typical antipsychotics.
    Han M; Zhang XY; Chen DC; Tan YL; Song CS; Yu YH; Huang XF
    Int Clin Psychopharmacol; 2015 Mar; 30(2):89-95. PubMed ID: 25568968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients.
    Scheltema Beduin AA; Swets M; Machielsen M; Korver N;
    J Clin Psychiatry; 2012 Nov; 73(11):1395-402. PubMed ID: 23218156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosiglitazone and cognitive function in clozapine-treated patients with schizophrenia: a pilot study.
    Yi Z; Fan X; Wang J; Liu D; Freudenreich O; Goff D; Henderson DC
    Psychiatry Res; 2012 Dec; 200(2-3):79-82. PubMed ID: 22727707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clozapine versus typical neuroleptic medication for schizophrenia.
    Wahlbeck K; Cheine M; Essali MA
    Cochrane Database Syst Rev; 2000; (2):CD000059. PubMed ID: 10796289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients.
    Lappin JM; Wijaya M; Watkins A; Morell R; Teasdale S; Lederman O; Rosenbaum S; Dick S; Ward P; Curtis J
    Schizophr Res; 2018 Sep; 199():367-373. PubMed ID: 29486959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clozapine treatment and discontinuation in Iceland: A national longitudinal study using electronic patient records.
    Ingimarsson O; MacCabe JH; Haraldsson M; Jónsdóttir H; Sigurdsson E
    Nord J Psychiatry; 2016 Aug; 70(6):450-5. PubMed ID: 27049594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: a cross-sectional study.
    Bressington D; Mui J; Tse ML; Gray R; Cheung EF; Chien WT
    BMC Psychiatry; 2016 Nov; 16(1):411. PubMed ID: 27863522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.
    Morrato EH; Dodd S; Oderda G; Haxby DG; Allen R; Valuck RJ
    Clin Ther; 2007 Jan; 29(1):183-95. PubMed ID: 17379060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescribing of Clozapine and Antipsychotic Polypharmacy for Schizophrenia in a Large Medicaid Program.
    Tang Y; Horvitz-Lennon M; Gellad WF; Lave JR; Chang CH; Normand SL; Donohue JM
    Psychiatr Serv; 2017 Jun; 68(6):579-586. PubMed ID: 28196460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of clozapine on cognitive functioning in treatment-resistant schizophrenic patients.
    Fujii DE; Ahmed I; Jokumsen M; Compton JM
    J Neuropsychiatry Clin Neurosci; 1997; 9(2):240-5. PubMed ID: 9144103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and predictors of metabolic syndrome among patients attending an outpatient clozapine clinic in Australia.
    Brunero S; Lamont S; Fairbrother G
    Arch Psychiatr Nurs; 2009 Jun; 23(3):261-8. PubMed ID: 19446781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of sole nurse and team-delivered community clozapine services for people with treatment-resistant schizophrenia.
    Gage H; Family H; Murphy F; Williams P; Sutton J; Taylor D
    J Adv Nurs; 2015 Mar; 71(3):547-58. PubMed ID: 25376164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing Clozapine Dispensing Trends in Queensland, Australia 2004-2013.
    Forrester T; Siskind D; Winckel K; Wheeler A; Hollingworth S
    Pharmacopsychiatry; 2015 Jul; 48(4-5):164-9. PubMed ID: 26091280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed initiation of clozapine may be related to poor response in treatment-resistant schizophrenia.
    Üçok A; Çikrikçili U; Karabulut S; Salaj A; Öztürk M; Tabak Ö; Durak R
    Int Clin Psychopharmacol; 2015 Sep; 30(5):290-5. PubMed ID: 26163875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.